New therapeutic options for bone diseases.
Wien Med Wochenschr
; 171(5-6): 120-125, 2021 Apr.
Article
em En
| MEDLINE
| ID: mdl-33512621
ABSTRACT
In recent years, new treatment options for both common and rare bone diseases have become available. The sclerostin antibody romosozumab is the most recently approved drug for the therapy of postmenopausal osteoporosis. Its anabolic capacity makes it a promising treatment option for severe osteoporosis. Other sclerostin antibodies for the treatment of rare bone diseases such as osteogenesis imperfecta are currently being investigated. For rare bone diseases such as Xlinked hypophosphatemia (XLH) and hypophosphatasia (HPP), specific therapies are now also available, showing promising data in children and adults with a severe disease course. However, long-term data are needed to assess a sustained benefit for patients.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Doenças Ósseas
/
Osteoporose Pós-Menopausa
/
Hipofosfatasia
Limite:
Child
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article